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Introduction: The global covid epidemic claims significant mortality and healthcare burden. The current study 
was conducted to assess clinical characteristics, predictors of severity, and outcome in terms of mortality of 
patients with Covid-19 infection.  
Materials and Methods: This descriptive cross-sectional study was conducted at the Department of Medicine, 
Capital Hospital Islamabad (Feb. 01, 2021, to April 25, 2021). The study included 221 adult patients of both 
genders, who presented with features suggestive of Covid-19. Detailed clinical evaluation, Covid PCR, 
radiological investigations, blood complete picture, and inflammatory markers (ferritin, D dimers, LDH, C-
reactive protein, interleukin-6 levels were performed). Based on the severity Index, patients were labelled as mild, 
moderate, or severe Covid. Patients were managed and followed till discharge or death. The association of covid 
severity was studied with the inflammatory markers, white cell counts, and outcome (i.e., death or recovery). 
Data analyzed by SPSS version 42, Chi-square applied as a test of significance and significant p< 0.05. 
Results: As per the severity index, 86(38.9%) cases had mild, 91(41.2%) had moderate and 44(19.9%) had severe 
Covid-19. Lymphopenia was observed in 154(69.7%), positive CRP 178(80.5%), raised serum ferritin 114(51.5%), 
raised D-dimers 139(66.9%), lactic dehydrogenase 167(75.5%) having a significant association with disease 
severity. Serum interleukin (performed in moderate and severe cases) had a mean value of 54.1+105.94pg/ml. 
Diabetes mellitus was found to be significantly associated with mortality (p=0.007) as well as hypertension 
(p<0.0001). 207 cases recovered and discharged; 14(6.33%) expired. 
Conclusion: Covid-19 is a disease with variable presentations.  The severity of Covid-19 infection is directly 
related to lymphopenia as well as elevated inflammatory markers. IL-6 levels, raised in more severe cases, that 
signify an immune response to Covid-19. The disease is more severe in patients with co-morbids.   
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Introduction 
 
The pandemic of Coronavirus disease (COVID-19) is 
far from being over. What started as an outbreak in 
Wuhan in November 2019 was eventually declared a 
global health concern by the World health 
organization (WHO) on March 11, 2020.1 
Since the first reports of Coronavirus cases from 
Wuhan, at the end of 2019, more than six million 
confirmed cases of COVID-19 have been reported 
globally, in all continents except for Antarctica.2 
Updated case counts in English can be found on the 
World Health Organization and European Centre for 
Disease Prevention and Control websites. 
Coronavirus disease is caused by SARS-C0V-2, which 
shares both structural and ancestral origin to SARS-
C0V-1 and MERS. The incubation period ranges from 
a minimum of 4 days to a maximum of 14 days with a 
mean value of 5.1 days.3,4 
Currently, the main transmission routes are via 
respiratory droplets and direct human-to-human 
contact in which virus is released in the respiratory 
secretions when an infected person coughs, sneezes, or 
talks. The infectivity of an affected individual is 2.5-
2.9. Hence general hygiene precautions, maintaining a 
safe distance, and wearing a facemask minimizes the 
risk of virus spread to a great degree. 
The spectrum of Covid symptoms ranges from 
common such as fever, dry cough, shortness of breath 
to less reported including gastrointestinal such as 
diarrhea and taste or olfactory issues. However, it can 
develop into severe pneumonia, ARDS, and even 
multi-organ failure. 
The disease process starts when the virus via its spike 
protein gets attached to the host cell and invades.5 
Once the virus gets inside a human body, it binds to 
the ACE-2 receptor expressed on alveoli and other 
cells and starts replicating. This results in damage to 
type-2 pneumocytes releasing specific inflammatory 
mediators which attract macrophages. Macrophages 
engulf the virus. IL-1, IL-6, TNF-alpha, and Interferon 
are released; this is called a cytokine storm. 
The standard method for diagnosing Covid-19 
infection is performing RT-PCR on nasopharyngeal or 
oropharyngeal swabs and a high-resolution CT scan of 
the chest.6 According to one study conducted in China, 
CT sensitivity was 97.2%, whereas the sensitivity of 
initial real time-PCR was 83.3%.  
The supportive hematological labs7,8 indicative of 
Covid-19 are lymphopenia and raised inflammatory 
markers such as serum ferritin, C-Reactive Protein, D-
dimers, Lactate dehydrogenase, troponin levels.  
There is no cure for Covid-19 disease and treatment is 
supportive aiming to alleviate symptoms and hasten 
recovery. Remdesivir, Tocilizumab, Corticosteroids, 
and Anticoagulants are among the main treatment 
modalities.9 Supportive therapy includes Vitamin-D, 
Zinc, and Vitamin C supplementation. 
The Covid-19 infection has been observed to be of 
variable severity. In this study of 221 patients, clinical 
symptoms, progress and various factors affecting 
disease severity and outcome of patients have been 
analyzed. The result from this duty will provide 
regional data of severity index in relation to 
demography, hematological parameters, inflammatory 
markers, and predictors of mortality. This may be 
helpful in the evaluation and management plan of 
Covid cases based on severity index and risk factors 
for better outcome and prognosis.  
 
Materials and Methods 
 
This was a hospital-based descriptive cross-sectional 
study. Patients included in the study were admitted to 
the COVID isolation ward and COVID wards A and B 
of the Medical Department at Capital Hospital, 
Islamabad from February 1st, 2021 to April 25th, 2021. 
The patients with the mild covid disease who were 
discharged from the emergency COVID room were not 
included in the study. The study was conducted after 
approval from the hospital ethical committee. The 
purpose and benefits of the study were explained to all 
patients and verbal consent was obtained 
The sample size was 221 cases. The sampling 
technique was non-probability consecutive sampling. 
Patients were of either gender and age 18 years and 
above. Detailed history and clinical examination were 
performed. Total 221 patients with clinical suspicion of 
Covid-19 infection were included in this study. 
Patients both Covid Real-time polymerase chain 
reaction (RT-PCR) positive and negative were 
included. In RT—PCR negative patients, inflammatory 
markers and radiological examination were used to 
detect the Covid-19 infection. Patients, less than 18 
years of age and Covid PCR negative patients with 
normal inflammatory markers were excluded from 
this study.  
Blood Complete Picture (CP), serum ferritin, lactate 
dehydrogenase (LDH), C-reactive Protein (CRP), D-
Dimers, and Interleukin-6 (IL-6) were noted. Reference 
normal range for Blood CP: WBC count of 4.5-10 per 
microliter, lymphocyte count 20-45%, LDH <480 U/I, 
CRP <10 mg/dl, IL-6 was <7pg/ml, D-dimers 
<500ng/ml and S. Ferritin <250ng/ml were 
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considered normal. We categorized the study group 
into mild, moderate, and severe groups. Chest x-ray 
and High-resolution computed tomography (where 
technically feasible) were performed too. 
Disease Severity: The confirmed Covid cases were 
clinically classified as mild, moderate, and severe/ 
critical disease according to the National Institute of 
Health (NIH) Pakistan guidelines published in 2020 
and defined as below; 
1. Mild Disease: 
 Presence of symptoms consistent with COVID 
without any hemodynamic compromise needs 
for oxygen or chest x-ray findings.  
 Oxygen saturation >94%. 
2. Moderate Disease:  
 Hypoxia (Oxygen saturation <94% but >90%) 
 Chest x-ray with infiltrates involving <50% of 
lung fields.  
 No complications and manifestations related 
to severe condition.  
3. Severe/ critical Disease: 
 In adults, clinical signs of pneumonia (fever, 
cough + any of the following) 
 Respiratory rate > 30/min 
 Severe respiratory distress 
 SPO2 <90% on room air 
 Chest X-ray involving >50% of lung fields 
 Multiple organ failure 
The data about the age, gender, disease level, 
presenting complaints, and inflammatory markers 
were entered into a proforma for collection and 
analysis. Data were analyzed using SPSS version 42. 
Mean value +/- S.D was determined for quantitative 
data (i.e., age, C-reactive protein, ferritin, d-dimers, 
LDH), and frequencies (%) were determined for 
qualitative data (i.e., gender, PCR status, Covid 
severity, presence or absence of lymphopenia, 
treatment received).  
Chi-square test applied as a test of significance to 
study the association of disease severity with PCR 
status, gender, lymphopenia, derangement of 
inflammatory markers, treatment received, and 
outcome in terms of mortality. P-value<0.05 taken as 
statistically significant. Data is presented in the form of 




Amongst 221 proven cases of Covid, there were 
125(56.6%) males and 96(43.4%) females. The mean 
age was 57.20+13.17 years with a range of 18-90 years. 
Total 155(70%) cases were Covid PCR +ve and the rest 
of 66(30%) cases were diagnosed based on contact 
history, inflammatory markers, and CT scan findings. 
As per the disease severity index, 86(38.9%) cases had 
mild covid, 91(41.2%) has moderate and 44(19.9%) had 
severe Covid.  
Lymphopenia (lymphocytes<20%) was observed in 
154(69.7%) cases and was found to be significantly 
associated with disease severity (Table 1, p=0.003). C-
reactive protein (as per laboratory cutoff value was 
positive in 178(80.5%) cases. There was a significant 
association of CRP with disease severity (p=0.001). 
Serum ferritin means the value was 367.9+464 ng/ml. 
As per the cut-off value of 250 ng/ml, it was raised in 
114(51.5%) cases having a significant association with 
disease severity (p<0.0001).  
The mean D-dimers were found to be 962+1853 
ng/ml. D-dimers were raised in 139(66.9%) Covid 
cases having significant association with disease 
severity (p=0.001). Serum LDH was raised in 
167(75.5%) cases and was significantly associated with 
disease severity (Table 1, p=0.025). Serum interleukin 
was performed only in certain cases according to the 
criteria for the performance of this costly investigation. 
Out of 103 cases in which interleukin-6 was performed 
the mean value observed was 54.1 + 105.94 pg/ml 
(maximum value observed was 590 pg/ml) 
Various co-morbid conditions were also studied in the 
study group. Diabetes was observed in 28(12.7%) cases 
out of 221. The expiry was observed in 05(17.9%) of 
diabetics as compared to 09(4.7%) of non-diabetics. 
Diabetes was significantly associated with mortality 
(p=0.007). Hypertension was observed in 21(9.5%) out 
of 221 cases. The expiry was observed in 06(28.6%) of 
hypertensives as compared to 08(4%) of non-
hypertensives. Hypertension was significantly 
associated with mortality (p<0.0001). Other co-morbid 
conditions observed were COPD in 4(1.8%), asthma 
2(0.9%), ischemic heart disease 4(1.8%), pulmonary 
tuberculosis 03(1.3%), CKD 2(0.9%), one case of 
hypothyroidism and lymphoma.  
There were 176(79.6%) cases out of 221 above 50 years 
of age. 27(15.3%) cases of >50 years age as compared 
to 01(2.2%) less than 50 years of age. Diabetes was 
significantly associated with age > 50 in admitted 
Covid cases (p=0.018).  Hypertension was seen in 
20(11.4%) of patients > 50 years of age and wasn’t 
significantly associated with age > 50 in admitted 
covid cases (p=0.062). 
Regarding the outcome in terms of mortality, 207 cases 
were managed and discharged and 14 cases expired. 
The mortality observed was 6.33%. Mortality was not 
found to be associated with gender or PCR status. 
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However, there was a significant association of 
mortality with disease severity, 25% of cases with 
severe disease expired Vs. <2.2% cases of mild to 
moderate disease (p<0.001). 
Mortality was also studied in relation to the treatment 
received, the 23.5% of the cases receiving both 
remedesvir and tocilizumab expired Vs. <5.6% expiry 
of the patients receiving remedesvir or none of these 
therapies (Table 2, Figure 2, p=0.008).  
 
Table 1: presenting the outcome of COVID cases in terms of mortality and association with gender, age, 
disease severity, PCR status, and anti-viral therapy (n=221) 



























 Lymphopenia (<20%) 









































































































Treatment Received      
 Remedesvir 
 Remedesvir & tociluzumab 
 None of these 
142(64.3%) 50(58.1%) 65(71.4%) 27(61.4%) <0.0001 
17(7.7%) 0(0%) 05(5.5%) 12(27.3%) 
62(28.1%) 36(41.9%) 21(23.1%) 05(11.4%) 
(Test of significance Chi-square test; significant p<0.05) 
 
Table 2: presenting the outcome of COVID cases in terms of mortality and association with gender, age, 
disease severity, PCR status, and anti-viral therapy (n=221) 
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 Moderate 























 Remedesivir Only 


















(Test of significance Chi-square test; significant p<0.05) 
 
 









The study aimed to measure the severity of Covid-19 
infection in the patients treated by the Department of 
Medicine in The Capital Hospital. It also evaluated the 
factors attributed to disease mortality.  
The analysis demonstrated that the most common 
symptoms of COVID-19 infected patients were fever 
(89%), body aches (86%), and dry cough (71%). Other 
symptoms were fatigue, shortness of breath, diarrhea, 
and vomiting. About 4% of the patient presented with 
a sole history of altered taste sensation. Few patients 
were asymptomatic. A study in Wuhan, China also has 
demonstrated various presenting symptoms of COVID 
patients.10 
The Republic of Korea developed a disease severity 
classification system for COVID 19-disease. Severity 
was measured by recording pulse rate, temperature, 
blood pressure, respiratory rates, and level of 
consciousness.11 In our study COVID 19 infection was 
also classified as mild, moderate, and severe. The 
disease was mild (38.9%) vs moderate (41.2%) vs 
severe (19.9%) in the hospitalized patients keeping in 
view that the majority of mild cases presenting in our 
hospital were not admitted and were discharged from 
the emergency Covid room on home treatment. 
Studies have shown that Pro-inflammatory cytokines 
play a pivotal role in the pathophysiology of tissue 
damage in COVID-19. There is a damaging immune 
reaction sustained by cytokines. Macrophages and 
monocytes infiltrate the alveoli. Uncontrolled 
inflammatory response results in cytokine storm and 
multi-organ failure.12 High CRP and IL-6 levels are 
associated with respiratory failure, mechanical 
ventilation, and mortality in COVID-19 patients.13 In 
our study we tested mostly IL-6 levels in severe Covid 
cases to look for the cytokine release syndrome. 
Although CRP was positive in the majority of cases in 
our study there was no statistical significance while 
evaluating the severity of the disease because in many 
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cases we had qualitative values of CRP only. As a 
result, we were not able to compare its value in the 
severity index. 
In Covid infection, there is leucopenia and 
lymphopenia. Lymphocytes express the coronavirus 
receptor ACE-2 and may be a direct target of the 
virus.14 Blood lymphopenia indicates the severity of 
COVID-19 patients.15 As a result, it also measures 
prognosis. In our study lymphopenia correlates well 
with the severity of disease (p=<0.003). 
The role of ferritin as a marker of inflammation is well 
known. Recently serum ferritin has been cited as one 
of the indicators of mortality.16 In our study serum 
ferritin was raised in severe COVID infection leading 
to increased mortality. 
The D-dimer level is used to measure and assess clot 
formation. In a cohort study, a significantly higher D-
dimer level (median 1.8 microgram/ml vs 0.5 
microgram/ml, p-value 0.001) was found in severe 
cases than in mild cases.17 Our study sowed D. dimer 
correlates well with the severity of disease (p=0.001) 
A pooled analysis has revealed that elevated LDH was 
associated with a 6-fold increased odds of severe 
COVID disease. It was associated with a more than 16-
fold increase in odds of mortality.18 In our study LDH 
level also increased with severity of disease 
(p<0.0001). 
Large scale data demonstrates that there is no gender 
difference in the proportion of people infected with 
COVID-19 infection but males are at a significantly 
higher risk of severe disease and death than females.19 
In our study mortality rate was slightly higher in 
males as compared to females. 
A study has shown that the mortality rate may rise 
and mild COVID disease may become severe 
especially in the elderly or the ones with comorbids.20 
Our study shows that the mean age is 64.71 in the 
patient who expired vs 56.87 in a discharged patient. 
In our study mortality was also high in patients with 
co-morbids i.e., Hypertension and Diabetes mellitus. 
A population-based cohort study of Denmark`s 
population has demonstrated that among in-patient 
COVID PCR positive patients, 21% (356 of 1657) died 
within 30 days which was a 3 to 3.1 fold increased 30 
days mortality rate when compared with COVID PCR 
negative in-patients (all P<0.001).21 In our study 
mortality was not associated with COVID PCR 
positive or negative status (p=0.476).  
According to WHO the only drug proven to increase 
COVID-19 survival rate is dexamethasone and steroids 
are recommended in severe disease. A trial in the USA 
National Institute of Health has shown that remdesivir 
has cut the time to recover from COVID19 infection 
from 15 to 11 days. A recent trial has shown that 
remdesivir was superior to placebo in shortening time 
to recovery in hospitalized COVID-19 infected 
adults.22 We gave remdesivir alone to 142(64.3%) 
admitted patients who were more symptomatic and 
were either having fluctuating oxygen saturation 
levels or impaired inflammatory markers, while no 
antiviral treatment was given to 62(28.1) stable 
patients.  Out of remdesivir treated 134 (94, 4%) 
patients were discharged vs 8(5.6%) and only 8(5.6%) 
expired. 
 A study reported tocilizumab reduced the likelihood 
of progression to the composite outcome of mechanical 
ventilation or death in hospitalized covid pneumonia 
patients, but it did not improve survival.23 In our study 
Tocilizumab and remdesivir combined were given to 
17(7.7%) patients with impending CRS. 13(76.5%)  
patients improved and discharged vs 4(23.5%) patients 
expired (p=0.008).    
There have been ongoing regional and international 
studies regarding the Covid. In view of the novelty 
and unpredictable course of illness, extensive research 
is required. The need of the time is to look for 
effective, efficient, sensitive, specific, and health care 
system-friendly diagnostic and therapeutic options. 
This study has real-time valuable data of 221 cases that 
were extensively investigated and managed despite 
epidemic burden and financial constraints. Certain 
limitations of the study that need to be mentioned are 
sampling technique, inability to perform interleukin-6 
in all cases due to financial constraints or 
recommendations, and the follow-up for long-term 
outcome in these cases. Despite these limitations, this 
study provides a valuable comparison of 
inflammatory markers and demography in relation to 
disease severity and mortality that can be an asset for 




Our study has shown that the severity of the Covid-19 
infection is directly related to a rise in inflammatory 
markers and COVID infection is more severe in elderly 
patients due to associated co-morbids resulting in 
impairment of the immune system. There is no 
mortality difference in Covid positive or negative 
patients. We suggest measurement of inflammatory 
markers and radiological examination to assess the 
severity of the disease in Covid-19 PCR negative 
patients. More comparative studies are needed to 
evaluate the role of antiviral treatment. Identifying 
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risk factors for early progression towards severe 
disease and mortality is fundamental in the 
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